A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation

1. Pope, S. D. & Medzhitov, R. Emerging principles of gene expression programs and their regulation. Mol. Cell 71, 389–397 (2018).

   Google Scholar 

2. Yosef, N. & Regev, A. Impulse control: temporal dynamics in gene transcription. Cell 144, 886–896 (2011).

   Google Scholar 

3. Sahin, M. & Sur, M. Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders. Science 350, https://doi.org/10.1126/science.aab3897 (2015).

4. Parikshak, N. N., Gandal, M. J. & Geschwind, D. H. Systems biology and gene networks in neurodevelopmental and neurodegenerative disorders. Nat. Rev. Genet. 16, 441–458 (2015).

   Google Scholar 

5. Lichti, J., Gallus, C. & Glasmacher, E. Immune responses – transcriptional and post-transcriptional networks pass the bBaton. Trends Biochem. Sci. 43, 1–4 (2018).

   Google Scholar 

6. Hawkins, L. J., Al-Attar, R. & Storey, K. B. Transcriptional regulation of metabolism in disease: From transcription factors to epigenetics. PeerJ. 6, e5062 (2018).

   Google Scholar 

7. Qi, L. S. et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 1173–1183 (2013).

   Google Scholar 

8. Gilbert, L. A. et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 442–451 (2013).

   Google Scholar 

9. Gemberling, M. P. et al. Transgenic mice for in vivo epigenome editing with CRISPR-based systems. Nat. Methods 18, 965–974 (2021).

   Google Scholar 

10. Konermann, S. et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517, 583–588 (2015).

    Google Scholar 

11. Zalatan, J. G. et al. Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. Cell 160, 339–350 (2015).

    Google Scholar 

12. Perez-Pinera, P. et al. RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat. Methods 10, 973–976 (2013).

    Google Scholar 

13. McCutcheon, S. R., Rohm, D., Iglesias, N. & Gersbach, C. A. Epigenome editing technologies for discovery and medicine. Nat. Biotechnol. 42, 1199–1217 (2024).

    Google Scholar 

14. Doudna, J. A. The promise and challenge of therapeutic genome editing. Nature 578, 229–236 (2020).

    Google Scholar 

15. Xu, X. et al. Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing. Mol. Cell 81, 4333–4345 (2021).

    Google Scholar 

16. Wang, X. et al. Robust miniature Cas-based transcriptional modulation by engineering Un1Cas12f1 and tethering Sso7d. Mol. Ther. 32, 910–919 (2024).

    Google Scholar 

17. Zhang, X. et al. Engineered circular guide RNAs enhance miniature CRISPR/Cas12f-based gene activation and adenine base editing. Nat. Commun. 16, 3016 (2025).

    Google Scholar 

18. Wu, Z. et al. Programmed genome editing by a miniature CRISPR-Cas12f nuclease. Nat. Chem. Biol. 17, 1132–1138 (2021).

    Google Scholar 

19. Su, M. et al. Molecular basis and engineering of miniature Cas12f with C-rich PAM specificity. Nat. Chem. Biol. 20, 180–189 (2024).

    Google Scholar 

20. Wu, Z. et al. Structure and engineering of miniature Acidibacillus sulfuroxidans Cas12f1. Nat. Catal. 6, 695–709 (2023).

    Google Scholar 

21. Wang, Q. et al. dCasMINI-mediated therapy rescues photoreceptors degeneration in a mouse model of retinitis pigmentosa. Sci. Adv. 10, eadn7540 (2024).

    Google Scholar 

22. Wu, R. et al. Activation of endogenous full-length utrophin by MyoAAV-UA as a therapeutic approach for Duchenne muscular dystrophy. Nat. Commun. 16, 2398 (2025).

    Google Scholar 

23. Syding, L. A., Nickl, P., Kasparek, P. & Sedlacek, R. CRISPR/Cas9 Epigenome editing potential for rare imprinting diseases: a review. Cells 9, https://doi.org/10.3390/cells9040993 (2020).

24. Goell, J. H. & Hilton, I. B. CRISPR/Cas-Based epigenome editing: advances, applications, and clinical utility. Trends Biotechnol. 39, 678–691 (2021).

    Google Scholar 

25. Na, E. S., Nelson, E. D., Kavalali, E. T. & Monteggia, L. M. The impact of MeCP2 loss- or gain-of-function on synaptic plasticity. Neuropsychopharmacology 38, 212–219 (2013).

    Google Scholar 

26. Liyanage, V. R. & Rastegar, M. Rett syndrome and MeCP2. Neuromolecular Med. 16, 231–264 (2014).

    Google Scholar 

27. Katz, N. et al. Tunable, self-contained gene dosage control via proteolytic cleavage of CRISPR-Cas systems. Preprint at https://doi.org/10.1101/2024.10.09.617463 (2024).

28. Ebina-Shibuya, R. & Leonard, W. J. Role of thymic stromal lymphopoietin in allergy and beyond. Nat. Rev. Immunol. 23, 24–37 (2023).

    Google Scholar 

29. Amati-Bonneau, P. et al. OPA1-associated disorders: phenotypes and pathophysiology. Int. J. Biochem. Cell Biol. 41, 1855–1865 (2009).

    Google Scholar 

30. Gao, Y. et al. Complex transcriptional modulation with orthogonal and inducible dCas9 regulators. Nat. Methods 13, 1043–1049 (2016).

    Google Scholar 

31. Zetsche, B., Volz, S. E. & Zhang, F. A split-Cas9 architecture for inducible genome editing and transcription modulation. Nat. Biotechnol. 33, 139–142 (2015).

    Google Scholar 

32. Nihongaki, Y. et al. CRISPR-Cas9-based photoactivatable transcription systems to induce neuronal differentiation. Nat. Methods 14, 963–966 (2017).

    Google Scholar 

33. Polstein, L. R. & Gersbach, C. A. A light-inducible CRISPR-Cas9 system for control of endogenous gene activation. Nat. Chem. Biol. 11, 198–200 (2015).

    Google Scholar 

34. Shao, J. et al. Synthetic far-red light-mediated CRISPR-dCas9 device for inducing functional neuronal differentiation. Proc. Natl. Acad. Sci. USA 115, E6722–E6730 (2018).

    Google Scholar 

35. Wang, X. et al. A far-red light-inducible CRISPR-Cas12a platform for remote-controlled genome editing and gene activation. Sci. Adv. 7, eabh2358 (2021).

    Google Scholar 

36. Zhou, Y. et al. A small and highly sensitive red/far-red optogenetic switch for applications in mammals. Nat. Biotechnol. 40, 262–272 (2022).

    Google Scholar 

37. Wu, Y. et al. Ultrasound Control of Genomic Regulatory Toolboxes for Cancer Immunotherapy. Nat. Commun. 15, 10444 (2024).

38. Li, T. et al. CRISPR/Cas9 therapeutics: progress and prospects. Signal Transduct. Target. Ther. 8, 36 (2023).

    Google Scholar 

39. Kim, D. Y. et al. Efficient CRISPR editing with a hypercompact Cas12f1 and engineered guide RNAs delivered by adeno-associated virus. Nat. Biotechnol. 40, 94–102 (2022).

    Google Scholar 

40. Chavez, A. et al. Comparison of Cas9 activators in multiple species. Nat. Methods 13, 563–567 (2016).

    Google Scholar 

41. Maeder, M. L. et al. CRISPR RNA-guided activation of endogenous human genes. Nat. Methods 10, 977–979 (2013).

    Google Scholar 

42. Mahata, B. et al. Compact engineered human mechanosensitive transactivation modules enable potent and versatile synthetic transcriptional control. Nat. Methods 20, 1716–1728 (2023).

    Google Scholar 

43. Klemm, S. L., Shipony, Z. & Greenleaf, W. J. Chromatin accessibility and the regulatory epigenome. Nat. Rev. Genet. 20, 207–220 (2019).

    Google Scholar 

44. Jaenisch, R. & Bird, A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. 33, 245–254 (2003).

    Google Scholar 

45. Jin, Y. et al. Interleukin-10 deficiency aggravates kidney inflammation and fibrosis in the unilateral ureteral obstruction mouse model. Lab Invest. 93, 801–811 (2013).

    Google Scholar 

46. Liao, H.-K. et al. In vivo target gene activation via CRISPR/Cas9-mediated trans-epigenetic modulation. Cell 171, 1495–1507 (2017).

47. Ye, H. & Fussenegger, M. Optogenetic medicine: synthetic therapeutic solutions precision-guided by light. Cold Spring Harb. Perspect. Med. 9, https://doi.org/10.1101/cshperspect.a034371 (2019).

48. Qiao, L. et al. A sensitive red/far-red photoswitch for controllable gene therapy in mouse models of metabolic diseases. Nat. Commun. 15, 10310 (2024).

    Google Scholar 

49. Choa, R. et al. Thymic stromal lymphopoietin induces adipose loss through sebum hypersecretion. Science 373, https://doi.org/10.1126/science.abd2893 (2021).

50. Zhou, B. et al. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat. Immunol. 6, 1047–1053 (2005).

    Google Scholar 

51. Al-Shami, A., Spolski, R., Kelly, J., Keane-Myers, A. & Leonard, W. J. A role for TSLP in the development of inflammation in an asthma model. J. Exp. Med. 202, 829–839 (2005).

    Google Scholar 

52. Wang, G. et al. Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity. Nat. Immunol. 20, 1494–1505 (2019).

    Google Scholar 

53. Jang, J. et al. Engineering of bidirectional, cyanobacteriochrome-based light-inducible dimers (BICYCL)s. Nat. Methods 20, 432–441 (2023).

    Google Scholar 

54. Wagner, T. E. et al. Small-molecule-based regulation of RNA-delivered circuits in mammalian cells. Nat. Chem. Biol. 14, 1043–1050 (2018).

    Google Scholar 

55. Gamboa, L. et al. Heat-triggered remote control of CRISPR-dCas9 for tunable transcriptional modulation. ACS Chem. Biol. 15, 533–542 (2020).

    Google Scholar 

56. Saito, H., Kubota, M., Roberts, R. W., Chi, Q. & Matsunami, H. RTP family members induce functional expression of mammalian odorant receptors. Cell 119, 679–691 (2004).

    Google Scholar 

57. Zolotukhin, S. et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6, 973–985 (1999).

    Google Scholar 

Download references